PMID- 23788306
OWN - NLM
STAT- MEDLINE
DCOM- 20140808
LR  - 20181203
IS  - 1898-018X (Electronic)
IS  - 1898-018X (Linking)
VI  - 20
IP  - 3
DP  - 2013
TI  - Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor 
      administration during primary percutaneous coronary intervention on long-term 
      left ventricular systolic and diastolic function.
PG  - 310-7
LID - 10.5603/CJ.2013.0077 [doi]
AB  - BACKGROUND: In primary percutaneous coronary intervention (PCI), glycoprotein 
      (GP) IIb/IIIa inhibitors are often given in order to attain and maintain better 
      myocardial perfusion. We tested the hypothesis that intracoronary (IC) bolus of 
      GP IIb/IIIa inhibitors might produce a greater improvement in left ventricular 
      (LV) systolic and diastolic function than an intravenous(IV) bolus. METHODS AND 
      RESULTS: Seventy seven patients undergoing primary PCI for their first ST 
      elevation myocardial infarction (STEMI) were randomly assigned to either an IC or 
      IV bolus of GP IIb/IIIa inhibitor, followed by IV infusion. Compared with the 
      echocardiographic findings within 3 days after PCI, LV ejection fraction was 
      higher at 1 year, with no significant differences between the IV and IC groups 
      (IV: 44% vs. 49%, p = 0.001; IC: 43% vs. 48%,p < 0.001). LV diastolic function 
      (E/E') did not significantly change at 1 year by either approach. CONCLUSIONS: LV 
      systolic function improved by a similar magnitude following primary PCI, with 
      either IC or IV bolus administration of GP IIb/IIIa inhibitor therapy. However, 
      no significant changes were observed in LV diastolic function.
FAU - Pellicori, Pierpaolo
AU  - Pellicori P
AD  - Department of Cardiology, Hull and East Yorkshire Medical Research and Teaching 
      Centre, MRTDS (Daisy) Building, Castle Hill Hospital, Cottingham, UK; Heart and 
      Great Vessel Department, Policlinico Umberto I, Sapienza University, Rome, Italy. 
      pierpaolo.pellicori@hey.nhs.uk.
FAU - Torromeo, Concetta
AU  - Torromeo C
FAU - Barilla, Francesco
AU  - Barilla F
FAU - Mangieri, Enrico
AU  - Mangieri E
FAU - Evangelista, Antonietta
AU  - Evangelista A
FAU - Truscelli, Giovanni
AU  - Truscelli G
FAU - Costanzo, Pierluigi
AU  - Costanzo P
FAU - Hoye, Angela
AU  - Hoye A
FAU - Wong, Kenneth
AU  - Wong K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Poland
TA  - Cardiol J
JT  - Cardiology journal
JID - 101392712
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Peptides)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - NA8320J834 (Eptifibatide)
RN  - X85G7936GV (Abciximab)
SB  - IM
MH  - Abciximab
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Coronary Vessels
MH  - Diastole/drug effects
MH  - Eptifibatide
MH  - Female
MH  - Humans
MH  - Immunoglobulin Fab Fragments/*administration & dosage
MH  - Infusions, Intravenous
MH  - Injections, Intra-Arterial
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnosis/physiopathology/*therapy
MH  - Peptides/*administration & dosage
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
MH  - Recovery of Function
MH  - Rome
MH  - Systole/drug effects
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Function, Left/drug effects
EDAT- 2013/06/22 06:00
MHDA- 2014/08/13 06:00
CRDT- 2013/06/22 06:00
PHST- 2013/06/10 00:00 [received]
PHST- 2013/06/10 00:00 [accepted]
PHST- 2013/06/22 06:00 [entrez]
PHST- 2013/06/22 06:00 [pubmed]
PHST- 2014/08/13 06:00 [medline]
AID - VM/OJS/J/34826 [pii]
AID - 10.5603/CJ.2013.0077 [doi]
PST - ppublish
SO  - Cardiol J. 2013;20(3):310-7. doi: 10.5603/CJ.2013.0077.